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Background: Uncomplicated lower urinary tract infections (UTIs) are common in women consulting primary
healthcare, taking up GP resources. Delayed consultation can increase the risk of serious infections such as pyelo-
nephritis or bacteraemia.
Objectives: To evaluate the effectiveness and uptake of a lower UTI test-and-treat service for women present-
ing with urinary symptoms within a community pharmacy in supporting self-care and appropriate use of
antibiotics and reducing demand on other NHS resources.
Methods: The service was aligned to national guidelines to diagnose and treat lower UTI in women aged
16–64 years and used national resources to provide safety-netting and self-care advice. Consultation included
clinical assessment and a urine dipstick test alongside a novel smartphone app, with diagnosis informed by
test results. Women were provided with safety-netting advice and either advised on self-care, supplied with
antibiotics or referred to their GP.
Results: Data were analysed for 764 women who presented to 23 pharmacies during December 2018 to April
2019. Lower UTI was found to be likely in 372/496 (75.0%) women, most of whom purchased antibiotics on the
same day. Had the service not been available, approximately three-quarters of women who had completed the
service and responded to the question would have visited their GP (214/301) and more than one-third would
have used self-care with or without going to see their GP (116/301).
Conclusions: A community pharmacy-led UTI test-and-treat service for women aged 16–64 years presenting
with urinary symptoms provided accessible and timely care aligned to national guidance, with 75.0% of consul-
tations requiring antibiotic treatment.
Introduction
Urinary tract infections (UTIs) are experienced by 10%–15% of
women each year1–3 and are the second most common condition
to be prescribed antibiotics in English primary care.4 A survey of
2424 women found that 95% who had a UTI consulted a health
professional for their symptoms and nearly two-thirds reported
visiting their local GP during routine consulting hours; in addition,
14% contacted an out-of-hours service.3
Antimicrobial resistance (AMR) is a global problem and the
UK Review on Antimicrobial Resistance has recommended all anti-
biotic prescriptions should be informed by data and testing tech-
nology to reduce inappropriate use.5 PHE has published guidance
to enable the diagnosis of lower UTI in women aged ,65 years
who present with urinary symptoms (herein referred to as ‘PHE UTI
guidance’) and defines three key urinary symptoms: dysuria,
new nocturia and cloudy urine (herein referred to as ‘PHE three
key symptoms’).6 A decision to treat with antibiotics can be
made in women with two or more of these symptoms, while
the additional use of a urine dipstick test may reduce diagnostic
uncertainty for women who have one of these symptoms;
however, up to 24% of women with a negative urine dipstick
test result may have a UTI, due to issues around poor urine
sample collection and the limited negative predictive values
of dipstick urinalysis.7 The UK’s Five-Year National Action Plan
aims to halve healthcare-associated Gram-negative blood-
stream infections by 20248 and NHS England improvement
schemes have focused on reducing the risk of Escherichia coli
bloodstream infections associated with the management of
UTI in the community.9
VC The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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Rapid diagnosis and effective early management can help
reduce serious urinary infections.10 An analysis of 1688 patients
with E. coli bacteraemia identified treatment for UTIs in the
preceding month being a major risk for bacteraemia due to non-
susceptibility of the pathogen. Close monitoring and effective
treatment of patients was recommended. In another study of bac-
teraemia, amoxicillin/clavulanic acid-resistant infections increased
in areas where use of the antibiotic was highest.11 Others
have found little risk of pyelonephritis in those not receiving antibi-
otics.12–14 However, early appropriate treatment of symptomatic
patients aged ,65 years would limit the risk of inappropriate
antibiotics being used.
Community pharmacy teams across the UK deliver a variety
of services to support antimicrobial stewardship, including
vaccination services and support for self-care. In addition, some
community pharmacy schemes have been developed to provide
pharmacy-led services to diagnose infections including group A
streptococcal infection and chlamydia.15,16 Accessible opening
times, convenient locations and no requirement for appointments
mean community pharmacies are well placed to support patients
with minor infections. The Community Pharmacy Contractual
Framework 2019–2024 includes details of a new NHS Community
Pharmacist Consultation Service to support urgent care referrals,
many of which are for minor infections, to community pharmacy
as the first port of call.17
There are pockets of community pharmacies across the UK that
are commissioned by the NHS to provide services for managing
UTIs; however, these vary greatly in eligibility criteria and method
of diagnosis (to test or not to test).18 Published studies of commu-
nity pharmacy-led UTI services report the use of clinical assess-
ment without the additional use of a urine dipstick test.19–21
The objective of this study was to evaluate a private pay, test
and treat service for women aged 16–64 years presenting with
urinary symptoms to community pharmacies, with a subsequent
diagnosis of uncomplicated lower UTI. The pilot tested the
feasibility of delivering a pharmacy-led service, with the aim of
understanding the effectiveness of the service in supporting self-
care, appropriate use of antibiotics and reducing demand for other
NHS resources.
Methods
The service was developed by a project team and an external expert advis-
ory panel, which included pharmacists, doctors and microbiologists.
Women aged 16–64 years presenting to the community pharmacy with
urinary symptoms were eligible to participate in the pilot service. They were
clinically assessed for the possibility of uncomplicated lower UTI, in line
with national diagnostic guidance, with treatment based on the outcome
of the urine dipstick test and NICE guidance NG109.6,22 The patient path-
way included advice on self-care, supply of antibiotics or referral to the GP,
as appropriate.
Pharmacists providing the service were trained using an e-learning
module, which included a clinical guide, practice scenarios and an online
test, and were encouraged to sign up as Antibiotic Guardians.23 Pharmacy
teams were provided with training material about the management of
UTIs, service protocol and a link to a short training video. Pharmacists
engaged with local GP surgeries to make them aware of the service.
Women found out about the service through discussions with pharmacy
staff, posters and leaflets displayed within the pharmacy.
Patient access to a smartphone able to use the DIP UTI test kit app was
required for the urine dipstick test (Healthy.io Ltd, Tel Aviv, Israel; nitrite:
sensitivity 99.3%, specificity 97.8%; blood: sensitivity 94.1%, specificity
95.3%; leucocytes: sensitivity 88.1%, specificity 95.2%). Exclusion criteria
included pregnancy, diabetes, kidney problems, fever, flu-like symptoms,
back pain or tenderness, nausea or vomiting, or vaginal discharge. Women
were also excluded if any of the following applied: had symptoms for more
than 7 days; were currently taking an antibiotic or had taken one within the
previous 4 weeks for a UTI; had two or more episodes of UTI in the last
6 months or three or more in the last 12 months; used a urinary catheter; or
were immunocompromised. Because patients with urinary catheters and
patients aged .64 years were excluded, and because patients had to walk
into a community pharmacy to access the service, it is unlikely that cases
would be hospital acquired.
A pharmacy advisor explained the service to the patient, recorded their
details, assessed them against the exclusion criteria and recorded the
patient-reported symptoms (burning pain when passing urine, passing
urine more often than usual at night, cloudy urine, blood in urine, needing
to pass urine more often than usual, sudden need to pass urine, pain or dis-
comfort in lower tummy). Eligible women who wanted to continue with the
service were then required to purchase the DIP UTI Self-Testing Kit (£9.99)
and download the free app. The app gave instructions to collect and ana-
lyse a mid-stream urine sample in a convenient location and stored the
test result on the individual’s smartphone to share on return to the same
pharmacy within 72 h. During the subsequent consultation, the pharmacist
then advised on the likelihood of a lower UTI (‘UTI likely’ or ‘UTI less likely’).
Treatment decisions were made on the outcome of the urine test result
(lower ‘UTI likely’ if sample positive for nitrite or for leucocytes and blood).6
Women who were determined to be likely to have a UTI were offered anti-
biotic treatment at an additional cost of £14.99. First-line treatment was
nitrofurantoin 100 mg prolonged-release capsules (one capsule twice daily
for 3 days), with nitrofurantoin 50 mg instant-release tablets (one tablet
four times a day for 3 days) where the formulation was unsuitable (e.g.
vegetarian option preferable). Where nitrofurantoin was clinically unsuit-
able, the second-line option was trimethoprim 200 mg tablets (one tablet
twice a day for 3 days). Treatment was supplied by the pharmacist under
the authority of a Patient Group Direction (PGD) and was in line with NICE
NG109 guidance.22 Pharmacists informed the women’s GP by letter of the
treatment within 24 h (where consent to do so was given).
All women were provided with safety-netting (e.g. expectation around
duration of symptoms; to see GP urgently if their symptoms worsened or
no improvement within 48 h) and self-care advice (e.g. symptom control,
future prevention advice) and a TARGET UTI leaflet.24 Individuals were
excluded from the service and referred to a doctor if they were pregnant or
had a recurrent UTI, symptoms for more than 28 days, recent UTI treated
with an antibiotic, urinary catheter or any of the following: visible haema-
turia as the only symptom, symptoms suggestive of a sexually transmitted
infection, renal impairment or diabetes. An urgent referral was made if the
individual was immunocompromised, had a fever or was systemically un-
well or had symptoms of upper UTI or pyelonephritis. Women were referred
urgently to accident and emergency if sepsis was suspected.
Data were collected through Boots UK pharmacies (a member of
Walgreens Boots Alliance, with headquarters in Nottingham). Data analysis
utilized Microsoft Excel 2013. The Carstairs index was used to calculate de-
privation quintiles (based on postal sector) for the least and most deprived
and is based on four census indicators (low deprivation indicated by a nega-
tive value, high deprivation by a positive value).25
Ethics
Anonymized copies of the data record were sent to the Boots UK head of-
fice for electronic input. The proposed work was reviewed by the Boots
Research Governance group and deemed to be a service evaluation and
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therefore in line with NHS Health Research Authority guidelines;26 ethics ap-
proval was not required.
Results
Data were collected for all women who used the service over a test
period of 4 months (11 December 2018 to 11 April 2019) across 23
participating pharmacies (21 in London, 2 in Sheffield). Incomplete
or illegible data were corrected by contacting participating phar-
macists to clarify data entry. Where this was not possible and the
data in question were of clinical importance to the analysis,
data were excluded (n"28). In total, 764 complete records were
returned for analysis (724 from London, 40 from Sheffield), repre-
senting 496/743 (66.8%) tests conducted during that time period
among all eligible women participating in the service and 360/379
(95.0%) antibiotics supplied (compared with transactional data
recorded).
Data on age were available for 745 women (unknown: n"19).
The mean age was 32 years and the median age was 29 years
(positively skewed distribution). Most women were aged between
16 and 35 years (71.3%, 531/745). Deprivation index was calcul-
able for 549 women and was normally distributed across the
Carstairs index (Figure 1). There appeared to be little difference in
the Carstairs index for those accessing the free components of the
service (initial upfront advice and consultation, mean 1.3) and
those that then went on to access the paid elements (test and/or
antibiotics, mean 1.2). Carstairs index was calculable for 89/121
(73.6%) women who chose not to continue with purchasing the
test despite being eligible, from which the mean was 1.4.
Of the 764 women that enquired about the service, 617
(80.8%) were eligible to participate (Figure 2). At this stage, 147/
764 (19.2%) women were ineligible to participate, reasons being:
two or more episodes of UTI in the last 6 months or three or more
in the last 12 months (62/764; 8.1%); symptoms lasting .7 days
(45/764; 5.9%); currently taking antibiotics or previous use of anti-
biotics for UTI within the last 4 weeks (24/764; 3.1%); or pregnancy
(3/764; 0.4%). Of those eligible to participate in the service, 496/
617 (80.4%) chose to purchase a test while 121/617 (19.6%) chose
not to continue with the service.
Urine dipstick test results indicated that 372/496 (75.0%) of
women were likely to have a lower UTI and were offered antibiotic
treatment. Of these, 360/372 (96.8%) women chose to purchase
antibiotics supplied by use of a PGD. Two women were excluded at
this stage due to ineligibility within the PGD criteria; the remaining
10 women chose not to continue due to reasons such as choosing
to watch and wait, or wishing to speak to their GP owing to other
complications. The majority of those that received treatment with-
in the pharmacy were supplied nitrofurantoin (352/360; 97.8%)
and where this was clinically unsuitable, trimethoprim was sup-
plied for eight women.
Data on symptom type were captured for 763/764 women
(Figure 3 shows symptom type by duration of symptoms) and indi-
viduals could select one or more from a list of seven symptoms.
Over three-quarters of women reported needing to pass urine
more often than usual (677/763; 88.7%), burning pain when pass-
ing urine (612/763; 80.2%), sudden need to pass urine (525/763;
68.8%), passing urine more often than usual at night (503/763;
65.9%) and pain or discomfort in lower tummy (482/763; 63.2%).
The mean number of symptoms per individual was 4.3 (median
4.0, range 1 to 7). On average, those women for whom the results
of the test indicated that a UTI was likely (n"372) had slightly
more symptoms (mean 4.5, median 5) compared with those for
whom the test indicated UTI was less likely (mean 3.8, median 4,
n"124). The mean duration of symptoms for women (n"743)
was 3.9 days (median 3 and mode 2). The data were positively
skewed owing to the number of women having symptoms for lon-
ger than 7 days (full range 1 day to 3 months). Once all women
with symptoms for over 7 days (n"45) were excluded, the mean
duration of symptoms for women with ‘UTI less likely’ and ‘UTI
likely’ test results was the same (3.0 days). There was little correl-
ation between positivity rate and duration of symptoms
(R2"0.0319).
National guidance for the diagnosis of UTI in women aged
,65 years recommends women with two or more of the PHE three
key symptoms are likely to have a lower UTI that requires antibiotic
treatment.6 The guidance does not recommend use of urine dip-
stick testing for these women, but does recommend testing in
women who only report one of the three symptoms. However, all
women with urinary symptoms participating in this pilot service
were required to use urine dipstick testing. Of those women who
met the PHE three key symptoms for ‘UTI likely’ (Table 1), 281/350
(80.3%) with two or three of these symptoms had a ‘UTI likely’ test
outcome, 83/123 (67.5%) women with one of the key symptoms
tested ‘UTI likely’ and 8/22 (36.4%) women with none of the key
symptoms tested ‘UTI likely’ (although they did have other symp-
toms recorded).
Figure 1. Deprivation profile for paid and non-paid elements of the service.
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The majority of women who accessed all elements of the
service did so on the same day (331/360; 91.9%). For those women
not completing all elements of the service on the same day,
they returned the following day (22/360; 6.1%) or within 3 days
(7/360, 1.9%).
Data indicating what action they would have taken if the service
had not been available were reported for 301/360 (83.6%) women
accessing both the urine dipstick test and subsequent treatment.
The majority of these women (214/301; 71.1%) would have gone
to their GP; over one-third would have attempted self-treatment
0
20
40
60
80
100
120
140
160
180
200
1 2 3 4 5 6 7 ≥8
N
um
be
r o
f p
a
en
ts
Duraon of symptoms (days)
Needing to pass urine more
oen than usual (n=664)
Burning pain when passing
urine (n=598)
Sudden need to pass urine
(n=515)
Passing urine more oen
than usual in the night
(n=493)
Pain or discomfort in your
lower tummy (n=473)
Cloudy urine (n=367)
Blood in your urine (n=131)
Figure 3. Frequency and duration of urinary symptoms (n"763).
Enquiries
(n=764)
Eligible for parcipaon
(n=617)
Purchased DIP UTI urine dipsck 
test
(n=496)
Test indicated 
‘UTI likely’
(n=372)
Supply of 
anbiocs
(n=360)
Women who were 
ineligible and given 
advice/referred to GP 
(n=147)
Test indicated 
‘UTI less 
likely’
(n=124) Women who were 
ineligible for 
anbiocs
(n=2)
Women who chose 
not to connue
(n=121)
Women who chose 
not to connue
(n=10)
Figure 2. Flow of women through stages of the service. Shaded boxes represent patients excluded or who withdrew from the service.
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as well or instead (116/301; 38.5%). Data on women who
accessed the test only were less representative, as data were only
available for 25.7% of women (35/136). Of these, 62.9% (22/35)
would have accessed their GP and 40.0% (14/35) would have self-
treated. Data were captured for five women who did not progress
beyond the initial screening protocol; four of these would have
accessed their GP and one would have self-treated.
Discussion
The service included use of the PHE UTI guidance to clinically as-
sess women before confirming eligibility to purchase a dipstick
test. By doing this, pharmacy staff were able to triage women
and give the most appropriate support, depending on the type and
severity of symptoms.
Of those that were eligible to purchase the test, one-fifth chose
not to do so. Women may have used the opportunity for discussion
with the pharmacy team to understand whether there was a need
to make a GP appointment (i.e. a ‘UTI likely’ test result) or accessed
local NHS services where they could get free treatment. This was
particularly the case in Sheffield, where 8/33 (24.2%) women
chose not to proceed with the community pharmacy service (ver-
sus 113/584; 19.3% in London), possibly due to ease of access to
the local NHS walk-in centre, which was opposite the pharmacy
participating in the service. Pharmacists were encouraged to liaise
with local GPs and service providers, as part of service training, to
understand referral pathways and guidelines so that they could
signpost appropriately.
For the purpose of the pilot, pharmacists used the PHE UTI guid-
ance to identify women who were not suitable for the service.
All women who were likely to have a lower UTI were required to
use a urine dipstick test and treatment decisions were made on
the outcome of the urine test result. This resulted in 69/350
(19.7%) women presenting with two or three of the PHE three key
symptoms not being treated with antibiotics (instead provided
with safety-netting advice), while eight women with none of the
PHE three key symptoms were treated with antibiotics. These
women presented with other clinical symptoms; however, these
findings reinforce the importance of treating the individual based
on the outcome of the assessment of clinical signs and symptoms
and not on the test alone. Certain symptoms such as cloudy urine
may be more difficult for women to notice (reported the least
frequently of the PHE three key symptoms in our data) and they
may place less importance on this compared with some of the
more symptomatic issues of frequent and painful urination.
Six percent of women (45/764) were excluded owing to having
had symptoms for longer than 7 days, indicating that many
women delay accessing services, increasing the risk of bacter-
aemia.10 The majority of women suffered from multiple symp-
toms, with the rate of the test result being ‘UTI likely’ increasing as
the number of symptoms increased.
The service was accessed by women of all ages (between 16
and 64 years) and levels of deprivation (based on the Carstairs
index) despite having to pay for the service directly. The potential
barrier of women having to visit the pharmacy on multiple occa-
sions (for initial assessment and to purchase the test, and
then again for the pharmacist to interpret the results and provide
treatment if appropriate) did not appear to be an issue. The major-
ity of women accessing all elements of the service did so on the
same day.
Data on what women would have done if the service had not
been available were mainly based on those that had completed all
elements of the service pathway, due to the point at which this
question was asked in the service pathway. The majority of these
women would have gone to their GP; therefore, this service would
be a direct substitution and cost saving if funded by the NHS.27,28
In addition, it would be more convenient as women would be able
to access the service without an appointment (potentially saving
time off work). Whilst data on those women who only accessed
testing are limited, almost two-thirds would have seen their GP if
the service had not been available, which would have been un-
necessary given that a UTI was less likely (therefore cost saving).
As pharmacists working within the community become more
integrated into primary care networks, there is an opportunity for
them to embed services such as this to support self-care and
appropriate use of NHS resources. This would support changing be-
haviour of patients with UTIs to utilize community pharmacies as
the first port of call (i.e. changing to a ‘pharmacy first’ mentality)
and allow for effective triage and treatment within this
environment. Whilst national recommendations exist on first-
and second-line treatments for UTI, there are examples of local
variations due to issues with resistance. Pharmacists need to
engage with local networks so that they can work with other
healthcare professionals to understand any variations in clinical
pathways or treatment options, but also to work collaboratively
in supporting the wider antimicrobial stewardship agenda.
There is an opportunity for pharmacy staff within the commu-
nity to help support patients with UTIs safely and effectively, in
line with clinical guidelines and treatment pathways, regardless
of whether this is funded by the NHS or the patients themselves,
as long as patients are triaged appropriately and safety-netting
advice is provided.
Limitations
The data presented are based on a private pay service and whilst
the clinical data are reflective of these women, it may not repre-
sent those that may have presented if the service was available
free of charge on the NHS. Data were more representative of
women accessing all elements of the service, compared with
those accessing the test alone, which gives less certainty in report-
ing activity for this patient group. Pharmacists utilized the PHE UTI
guidance as part of the service delivery as fully as they could, but
were unable to send urine samples for culture. There were also no
Table 1. Test outcome based on PHE three key symptoms: dysuria, new
nocturia and cloudy urine (data available n"495)
Number of the PHE three key symptoms
two or three
(n"350)
one
(n"123)
zero
(n"22)
Test outcome
‘UTI likely’
281 (80.3%) 83 (67.5%) 8 (36.4%)
Test outcome
‘UTI less likely’
69 (19.7%) 40 (32.5%) 14 (63.6%)
UTI test-and-treat service in community pharmacies JAR
5 of 7
D
ow
nloaded from
 https://academ
ic.oup.com
/jacam
r/article/2/1/dlaa010/5802825 by U
niversity of Leeds user on 02 August 2021
data available on patient follow-up (e.g. recurrent symptoms,
treatment failure rates, hospital admissions); therefore, data on
what patients would have done if the service were not available
may not be truly representative of their opinion after resolution of
their infection. It would be useful to include this in future service
evaluations.
Conclusions
Pharmacy teams were able to support females aged 16–64 years
with uncomplicated lower UTI within the community pharmacy.
Women were provided with self-care advice, treatment (if neces-
sary) or triaged to a more appropriate service. The service helped
to support the appropriate use of antibiotics and reduced demand
on other NHS resources such as GP surgeries and urgent care
settings. The recommendations to base diagnosis on clinical
symptoms guided by appropriate use of urine dipstick testing (not
just based on the test result alone) have already been incorporated
in future service design.
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